Background: Sleep-disordered breathing (SDB) is thought to be a state of inflammation caused by hypoxic stress. Whether adaptive servo ventilation (ASV) attenuates the inflammatory response and improves the cardiac function of patients with congestive heart failure (CHF) accompanied by SDB was not been investigated.
hronic heart failure (CHF) is a leading cause of death in developed countries and is often encountered in clinical practice. Many studies have shown that pharmacological therapies (eg, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockers) and non-pharmacological treatments (eg, cardiac resynchronization) can improve cardiac function and clinical symptoms and reduce mortality in patients with CHF. 1-4 Despite this progress in both medical and surgical management, CHF is associated with high mortality and a poor quality of life. 5 Therefore, the development of novel therapeutic treatments for CHF is desirable.
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Recent studies have provided strong evidence that serum inflammatory cytokine levels are elevated in patients with CHF, and the inflammatory response is an important contributor to disease progression. 6,7 A progressive increase in proinflammatory cytokine expression is closely related to an increase in functional heart failure classification. 8 One clinical study showed that short-term statin therapy improved cardiac function and symptoms in patients with dilated cardiomyopathy through an anti-inflammatory mechanism. 9 These results imply that anti-inflammatory therapies represent a novel treatment approach for CHF.
Sleep-disordered breathing (SDB) is characterized by snoring, insufficient sleep, daytime sleepiness, and the cessation of breathing. SDB is prevalent in patients with CHF. Central sleep apnea occurs in aproximately 40% of patients with heart failure, and SDB is an important causative factor in worsening cardiac function 10 and increasing the risk of cardiac death. 11 Moreover, serum C-reactive protein (CRP) levels are elevated in patients with obstructive sleep apnea syndrome due to repetitive hypoxia. 12 The inflammatory response is closely associated with the degree of obstructive sleep apnea.
Adaptive servo-ventilation (ASV; Autoset CS, ResMed, Sydney, Australia) automatically adjusts its settings based on an analysis of the patient's breathing effort and maintains steady minute ventilation. 13 One study suggested that ASV treatment was effective for patients who were resistant to continuous positive airway pressure (CPAP); 14 therefore, ASV Effects of ASV for Heart Failure is used frequently for patients with central sleep apnea. 15 A recent study demonstrated that CPAP therapy reduced the frequency of apnea and hypopnea and improved cardiac function in patients with CHF, resulting in improved heart transplant-free survival. 16 However, there is considerable uncertainty regarding the efficacy of ASV treatment in patients with heart failure.
This study tested the hypothesis that sleep-disordered respiration elicits an inflammatory response, and that the antiinflammatory effect of ASV can be an important candidate for improving cardiac function and clinical states in patients with CHF accompanied by SDB.
Methods

Study Population
This study enrolled 17 consecutive patients with CHF (New York Heart Association [NYHA] functional class II or III) who were referred for an overnight polysomnography (PSG) to screen for sleep disorders at our sleep center at Akita University Hospital. All patients provided written informed consent regarding the study protocol, which was approved by the clinical research and ethics committee of the University of Akita. Patients were included for the following reasons: (1) a history of worsening heart failure; (2) CHF with an ejection fraction below 55% as measured by ultrasonic echocardiography in outpatient visits; (3) symptoms related to sleep apnea, including episodes of loud snoring, excessive daytime sleepiness, nocturnal dyspnea, and restless sleep; or (4) an apnea and hypopnea index (AHI) ≥15 /h with a majority of central sleep apnea events. Patients were excluded if they had any of the following conditions: acute myocardial infarction, acute pneumonia, severe chronic obstructive pulmonary disease, psychotic disorders, pharyngeal disease, poor drug compliance, current smokers, or a history of severe cerebral infarction.
Study Design
All participants were required to: (1) complete a questionnaire designed to assess their risk of heart failure, including a determination of the patient's NYHA functional class; (2) complete the Epworth Sleepiness Scale (ESS) questionnaire; (3) undergo an echocardiogram to determine the left ventricular ejection fraction (LVEF); (4) undergo a sleep study with conventional PSG; and (5) undergo routine blood tests. The patients then had an ASV device set and it was decided whether they would receive ASV treatment. Some patients refused positive airway pressure treatment because of the discomfort of wearing a mask or positive airway pressure. Consequently, the patients were divided into 2 groups: (1) those receiving ASV treatment (ASV-treated group); and (2) those not receiving ASV treatment (non-ASV-treated group; Figure 1 ). Various biophysical parameters were compared between the 2 groups before and after ASV treatment. Before ASV treatment, all participants had a 2-week rest period to eliminate the effects of rest and diet on improved cardiac function. After the 2-week rest period, ASV treatment was initiated the day after conventional PSG by experienced physicians. PSG was repeated to determine the respiratory condition during treatment, and the AHI score and the apnea index (AI) score were evaluated. For those who received drug treatment only, PSG was also performed 4 weeks after the initial analysis. Various biophysical markers and echocardiographic parameters were measured before and after ASV treatment in both groups.
Sleep Study
All patients underwent an overnight complete PSG using the ProFusion PSG ® Sleep Diagnostic System (Compumedics, Victoria, Australia), which continuously monitors the electroencephalogram, electrooculogram (used in sleep staging), oxygen saturation (SaO2), airflow, snoring, and thoracoabdominal motion. Apnea was defined as an absence of inspiration without ribcage and abdominal motion for ≥10 s; hypopnea was defined as a ≥30% reduction in monitored airflow accompanied by a decrease in SaO2 of ≥4%. Arousal responses were defined according to the recommendations of the American Sleep Disorders Association. The AHI was defined as the number of apnea and hypopnea episodes per hour of sleep. An AHI >15 /h was defined as moderate to severe SDB. A diagnosis of central sleep apnea was assigned at an AHI of >15 /h, with >50% of the events labeled as central rather than obstructive. 
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ASV Treatment
During the resting period, each patient selected a mask based on comfort from a fixed range and was trained by an experienced sleep technician on the principals and use of the ASV system (Autoset CS ® ; ResMed). Those patients who agreed to ASV treatment then underwent 4 h of acclimation (quiet rest in a supine position). Adjustments were made by physicians who were familiar with the ASV treatment. An expiratory positive airway pressure (EPAP) of approximately 4 cmH2O and an inspiratory pressure support between 3 and 10 cmH2O were used. Over the first 20 min of treatment, the patient's heart rate, SaO2, and blood pressure were monitored every 5 min. EPAP was manually titrated every 0.5 cmH2O to a maximum of 6 cmH2O if no respiratory events were eliminated using the default setting. During the initial 3 days of treatment period, observations pertaining to whether the patients could wear their ASV device during their entire sleeping time were undertaken. Patients who had insufficient ASV use during their sleep were defined as the non-ASV group. These patients were observed without ASV treatment during the follow-up period.
Echocardiography Two-dimensional, M-mode, and Doppler echocardiography (Sequoia 512, Siemens, Erlangen, Germany) were performed to evaluate various parameters of heart function in the patients. The LVEF was determined from an apical 4-chamber view using Simpson's method. The sonographers were blinded to the PSG results and were not involved in the treatment of these patients.
Statistical Analysis
Continuous variables are expressed as the mean ± standard deviation. For continuous and normally distributed data, Student's t-test was used to compare between groups; for non-normally distributed data, the Mann-Whitney U-test was used. Correlations were analyzed using Pearson's correlation coefficient. A P value <0.05 was considered statistically significant. All statistical analyses were performed with SPSS for Windows ver. 16.0 (SPSS, Chicago, IL, USA).
Results
A flow diagram of the study is shown in Figure 1 . Seventeen consecutive patients were enrolled. Ten patients agreed to continue ASV treatment (ASV-treated group) and were successfully titrated on ASV (AHI ≤10/h), whereas 7 patients declined the therapy (non-ASV-treated group) or had insufficient ASV use because of mask intolerance (n=4) or subjective intolerance to positive airway pressure (n=3). After a 2-week rest period, the ASV-treated group received treatment individually for 4 weeks. Various parameters, includ- Effects of ASV for Heart Failure ing PSG monitoring, laboratory data, and echocardiographic findings, were recorded before and after ASV treatment. The non-ASV-treated patients were observed for 4 weeks, and then the same parameters were measured. The baseline characteristics of the patients are summarized in Table 1 . No patient experienced a potential complication or changed the study protocol during the follow-up period. Before ASV treatment, no significant difference was observed in mean age, gender ratio, prevalence of structural heart disease, pharmacological treatment (ACE inhibitors, angiotensin II receptor blockers, β-blockers, diuretics, aldosterone antagonists, or statins), echocardiographic parameters, or laboratory data between the 2 groups. The baseline sleep study data are shown in Table 2 . No difference was observed between the ASV-treated group vs the non-ASV-treated group in terms of AHI score (36.6±15.8 vs 33.1±16.8, respectively), arousal index (28.4±17.1 vs 33.0±28.3, respectively), mean SaO2 (94.8±1.9 vs 94.0±2.0%, respectively), or minimum SaO2 (83.7±5.6 vs 83.6±2.9%, respectively) at baseline. The ASV-treated patients continued ASV treatment during the follow-up period after their hospital stay. The non-ASVtreated patients also continued therapy during their hospital stay, without any prescription changes.
The PSG recordings of the 2 groups before and after 4 weeks of ASV treatment are compared in Table 2 . Both the AHI and AI decreased significantly in the ASV-treated group (AHI, 36.6±15.8 to 4.7±3.3, P<0.01; AI, 22.8±11.6 to 0.8±1.3, P<0.01), but not in the non-ASV-treated group (AHI, 33.1±16.8 to 33.9±21.7, P=0.94; AI, 24.1±16.7 to 22.5±19.7, P=0.88). The change in the mean SaO2 level was greater in the ASV-treated group (94.8±1.9 to 96.4±1.2%, P=0.04) than in the non-ASV-treated group (94.0±2.0 to 95.1±0.9%, P=0.20). However, the lowest SaO2 levels before and after ASV use in both groups did not differ significantly. Patient physiological changes and the quality of sleep data are also presented in Table 2 . The ESS score also decreased in the ASV-treated group (the proportion of patients with an ESS score ≤16 increased from 60 to 100%, P=0.02), compared to no change in the non-ASV-treated group (an increase from 86 to 100%, P=0.34). During the follow-up period, the NYHA functional class improved in the ASV-treated group (ie, the proportion of patients in NYHA class I−II increased from 50 to 100%, P=0.01), but not in the non-ASV-treated group (an increase from 43 to 57%, P=0.63). There were no significant differences in the change in BMI in either group. Systolic blood pressure (128.8±22.1 to 126.9±16.6 mmHg, P= 0.49), diastolic blood pressure (76.2±13.1 to 74.0±8.6 mmHg, P=0.76), and heart rate (66.0±8.2 to 66.2±8.1 mmHg, P=0.96) did not change during the follow-up period in the ASV-group. In the non-ASV group, systolic blood pressure (119.4±13.4 to 114.3±7.3 mmHg, P=0.70), diastolic blood pressure (65.7± 14.0 to 64.6±12.3 mmHg, P=0.74), and heart rate (60.8± 14.1 to 60.7±10.9 mmHg, P=0.75) did not differ significantly during the follow-up period. r=0.753 p=0.016 Figure 2 . Correlation between the AHI score and hs-CRP level in patients with CHF accompanied by SDB. AHI, apnea hypopnea index; hs-CRP, high-sensitive C-reactive protein; CHF, chronic heart failure; SDB, sleep-disordered breathing.
KOYAMA T et al. Figure 2 shows the correlation between the AHI score and high-sensitivity C-reactive protein (hs-CRP) levels in patients with CHF accompanied by SDB. The hs-CRP levels and AHI score were positively correlated in patients with heart failure (r=0.753, P=0.016). The echocardiographic data before and 4 weeks after ASV treatment are shown in Figure 3 . LVEF improved significantly in the ASV-treated group (43.5±6.4 to 53.3±6.1%, P=0.002) compared to the non-ASV-treated group (45.7±9.5 to 45.6±9.7%, P = 0.90). The reduction in plasma brain natriuretic peptide (BNP) levels was greater in the ASV-treated group (212.1±181.2 to 77.3±54.0 pg/ml, P= 0.04) than in the non-ASV-treated group (293.3±149.1 to 246.0±145.4 pg/ml, P=0.33; Figure 4) . Next, we examined the inflammatory response in patients with a sleep disorder and heart failure, and its short-term fluctuations. The reduction in plasma hs-CRP levels was more evident in the ASVtreated group (0.85±0.58 to 0.21±0.19 mg/dl, P=0.008) than in the non-ASV-treated group (0.79±0.75 to 0.80±0.79 mg/dl, P=0.90; Figure 5 ). Figure 6 shows the relationship between the change in LVEF and hs-CRP levels in those patients with CHF accompanied by SDB; these were negatively correlated (r=-0.733, P=0.001).
Discussion
This study provides several major insights into the therapeutic effect of ASV in patients with CHF and SDB. First, ASV treatment reduced the AHI, AI, and ESS scores and improved the quality of sleep in CHF patients with SDB ( Table 2) . This is consistent with a previous study showing that CPAP treatment improved the quality of life of patients with both CHF and SDB. 17, 18 Second, ASV treatment improved cardiac function, as indicated by an increased LVEF and decreased plasma BNP levels (Figures 3, 4) . Furthermore, this improvement Effects of ASV for Heart Failure occurred over a relatively short period. Recently, ASV was shown to improve cardiac function and symptoms in patients with CHF; however, SDB became apparent several months after the start of ASV treatment. 19 It should be emphasized that improvements in cardiac function and the laboratory parameters occurred after only 4 weeks of ASV treatment in our study. Third, the magnitude of hs-CRP elevation, an important marker of systemic inflammation, was positively correlated with the severity of AHI, which is consistent with the findings from a previous report (Figure 2) , 12 indicating that repetitive hypoxic stress might induce systemic inflammatory responses in patients with CHF. Finally, the change in serum hs-CRP levels was negatively correlated with the change in LVEF, implying that preventing an inflammatory response by ASV therapy is one of the important contributors for improving cardiac function ( Figure 5 ). Improved cardiac function in patients with CHF is correlated with the treatment of sleep-disordered respiration through CPAP therapy. 16 ASV was designed to treat respiratory disturbances during sleep by improving respiratory conditions and sleep quality through automatic adjustments in ventilation parameters. It was previously shown that ASV improved SDB in patients who were resistant to CPAP. 14 However, very few studies have examined the effectiveness of ASV in patients with CHF accompanied by SDB. In addition, the precise mechanism of CPAP-or ASV-induced effects in the management of heart failure has not been determined. In this study, we focused on the inflammatory response as an important causative factor in worsening heart failure.
In patients with obstructive sleep apnea syndrome, a clinical trial has already shown that serum CRP levels are closely associated with the severity of apnea. There is also a good correlation between serum CRP levels and the AHI score. 20 One important factor in CRP elevation in patients with obstructive sleep apnea is overnight repetitive hypoxic stress. 12, 21 Repetitive hypoxia contributes to the release of inflammatory cytokines, adhesion molecules, and free radical production. 12 Proinflammatory cytokines such as interleukin (IL)-6 are the primary determinants of hepatic CRP production. 22 Because hypoxia-induced serum proinflammatory cytokine production is an important contributor to chronic systemic inflammation in patients with CHF and SDB, serum CRP levels might represent a useful surrogate marker for cardiac damage caused by proinflammatory responses.
Recently, heart failure was identified as an inflammatory disease, and serum CRP levels have been shown to be independently related to mortality and morbidity in patients with heart failure. 23 Serum CRP levels are associated with an increased risk of developing heart failure in elderly subjects 24 and are correlated with left ventricular remodeling and contractile dysfunction. 25 Proinflammatory cytokines appear to induce myocyte apoptosis and necrosis, 26 whereas CRP has adverse effects on vascular endothelium by reducing nitric oxide release and inducing the expression of endothelial adhesion molecules. 8 Furthermore, proinflammatory cytokines affect electrophysiological function and have an acute negative inotropic effect on cardiomyocytes. 27 Therefore, these inflammatory reactions could be responsible for left ventricular dilatation and decreased left ventricular contractile function in patients exposed to repetitive hypoxia. A previous study showed that CPAP therapy for patients with p=0.008 p=0.9
A B Figure 5 . Comparison of high-sensitive C-reactive protein (hs-CRP) levels at baseline and after 4 weeks in patients treated with (A) and without adaptive servo ventilation (B).
r=-0.733 p=0.001 Figure 6 . Correlation between the change in the left ventricular ejection fraction (LVEF) and high-sensitive C-reactive protein (hs-CRP) level in patients with congestive heart failure accompanied by sleep-disordered breathing.
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obstructive sleep apnea markedly decreased the inflammatory response, as evidenced by decreased serum CRP and IL-6 levels. 21 Our results demonstrate that ASV treatment improves the cardiac condition of patients with CHF and SDB; thus, ASV might constitute a new treatment paradigm, targeting heart failure as an inflammatory disease. One limitation of this study is that we could not evaluate the serum levels of cytokines, such as IL-6 and TNF-α, to assess the systemic proinflammatory response caused by CHF and repetitive hypoxia. Therefore, the relationship between the degree of heart failure and proinflammatory changes was not analyzed. In this study, 40% of the patients could not wear the ASV device throughout their entire sleeping time. We did not examine whether short-duration ASV use was effective in this study. Further study is needed to clarify this point.
In conclusion, preventing inflammatory responses by ASV treatment is one of the important contributors for improving cardiac function, supporting the efficacy of anti-inflammatory therapy for patients with CHF.
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